Please login to the form below

Not currently logged in
Email:
Password:

Therachon poaches Shire’s Aled Williams

He becomes the biotech’s chief commercial officer and head of patient access

Aled WilliamsTherachon, a clinical-stage biotechnology company, has appointed Aled Williams to the position of chief commercial officer and head of patient access.

Williams has more than 25 years’ experience in healthcare and pharmaceuticals and most recently he served as vice president and global strategy head for rare gastrointestinal diseases at Shire.

There he was responsible for the commercialisation and development of Gattex/Revestive (teduglutide) for short bowel syndrome.

Williams said: “I am excited to be joining the talented leadership team at Therachon and I look forward to working with the Therachon team and the whole medical and patient community in developing TA-46, and advancing Therachon’s pipeline of drug candidates that aim to bring a transformational new therapy to those in the achondroplasia community.”

Prior to his time at Shire, Williams held leadership positions at Bristol-Myers Squibb, Novartis and Roche.

Commenting on the recent appointment, Luca Santarelli, chief executive officer of Therachon, said: “Aled has spent many years leading companies through the development of successful rare disease programmes, including the expansion of patient outreach and commercial capabilities.

“We believe his considerable leadership experience in rare diseases will contribute to Therachon’s continued growth as we move into the clinic, establish our network of key partners among clinicians and patient organisations.”

23rd March 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics